Innovative synthetic biology techniques are revolutionizing microbiota-based therapies, enhancing microbial functions for ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

Colossal Biosciences is working to bring back species like the woolly mammoth using CRISPR-Cas9 technology. The project aims to restore lost biodivers ...

The field of cancer research is rapidly evolving, with a growing focus on the intersection of cancer immunology, gene editing, and epigenetics. This ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Arkadios Wealth Advisors lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

This is a useful study that seeks to address the role of the TET family of DNA demethylation enzymes in pancreatic beta cell senescence in the context of type 2 diabetes (T2DM). Although the concepts ...